June 1, 2016 - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) (“OncBioMune” or the “Company”), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, announced that it will be presenting at the 6th annual LD Micro Invitational on Wednesday, June 8 at 2:30 PM PST / 5:30 PM EST. Andrew Kucharchuk, President and Chief Financial Officer at OncBioMune, will be giving the presentation and meeting with investors.

“Against the backdrop of all the exciting developments recently with ProscaVax, our novel prostate cancer vaccine, I look forward to personally sharing and interacting with the investment community next week,” said Mr. Kucharchuk.

The conference will be held at the Luxe Sunset Bel Air Hotel and will feature 195 companies in the small / micro-cap space.

View OncBioMune’s profile here: http://www.ldmicro.com/profile/OBMP

Profiles powered by LD Micro - News Compliments of Accesswire

About OncBioMune Pharmaceuticals, Inc.

OncBioMune Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a proprietary Vaccine Technology that is designed to stimulate the immune system to attack its own cancer while not hurting the patient. Our lead product, ProscaVax® is scheduled to commence a Phase 2 clinical study in 2016. OncBioMune also has a portfolio of targeted therapies, some of which are biosimilars to blockbuster drugs. OncBioMune is headquartered in Baton Rouge, LA.

This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering, nor there be any sale of these securities in any jurisdiction in which such offer solicitation or sale are unlawful prior to registration or qualification under securities laws of any such jurisdiction.

About LD Micro

LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into an event platform hosting several influential conferences annually (Invitational, Summit, and Main Event).

In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and microcap universe.

For those interested in attending, please contact David Scher at [email protected] or visit www.ldmicro.com for more information.

Contact:

Name: Andrew Kucharchuk, President, CFO, OncBioMune Pharmaceuticals, Inc.
Phone: 1-225-227-2384
Address: 11441 Industriplex Blvd., Suite 190, Baton Rouge, LA, 70809
Email: [email protected]